The results from this independent verification study further demonstrate that both Luminal B and HER2-enriched breast cancer are predictive of poorer distant recurrence free survival compared to Luminal A breast cancer in an ER+ node-negative tamoxifen-treated early-stage breast cancer population (a set containing very few basal-like subtype patients). Here, ESR1 is linked to breast carcinoma.